HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.4%

Neg 0% Neu 89.4% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.